4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a

P.de Souza; K.Maart; A.Laurell; R.E.Hawkins; A.Berkenblit; L.Galand; A.Thiele; A.Strahs; J.Feingold; G.Hudes

首页> 外文期刊>European Journal of Cancer Supplements >4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a

【24h】

4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a

机译：4011 POSTER接受坦索罗莫司，干扰素-a或坦索罗莫司+干扰素-a联合治疗的晚期肾细胞癌（RCC）和预后不良的患者的3期随机研究结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共2页
作者
P.de Souza; K.Maart; A.Laurell; R.E.Hawkins; A.Berkenblit; L.Galand; A.Thiele; A.Strahs; J.Feingold; G.Hudes;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. [J] . Bellmunt J, Szczylik C, Feingold J, Annals of oncology: official journal of the European Society for Medical Oncology . 2008,第8期

机译：替莫罗莫司对晚期肾细胞癌和预后不良的患者的安全性和毒性作用的管理。
2. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features [J] . J. Bellmunt1 C. Szczylik2 J. Feingold3 A. Strahs3 and A. Berkenblit3 Annals of Oncology . 2008,第8期

机译：替莫罗莫司对晚期肾细胞癌和预后不良的患者的安全性和毒性作用的管理
3. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study [J] . Merchan Jaime R., Qin Rui, Pitot Henry, Cancer chemotherapy and pharmacology. . 2015,第3期

机译：替西罗莫司和贝伐单抗在先前用酪氨酸激酶抑制剂治疗的晚期肾细胞癌患者中的安全性和活性：2期联合研究
4. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor RAF Kinase and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804) [O] . Keith T. Flaherty, Judith B. Manola, Michael Pins, -1

机译：最佳：一项针对晚期肾细胞癌的血管内皮生长因子RAF激酶和雷帕霉素联合靶向治疗与贝伐单抗索拉非尼和替米罗莫司联合靶向治疗的随机II期临床研究-ECOG-ACRIN癌症研究小组的一项试验（E2804）
5. PCN126 LOSS OF WORK ACTIVITY AND PRODUCTIVITY IN CAREGIVERS ATTENDING TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH TEMSIROLIMUS OR INTERFERON-ALFA: EVALUATIONS FROM A PHASE 3 RANDOMIZED TRAIL [O] . Yang S, Alemao E 2009

机译：PCN126对经晚期肺细胞癌患者治疗，经特异肺炎或干扰素-α治疗的食管癌患者的工作效率和生产率下降：来自第3阶段随机轨迹的评估

4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a

著录项

相似文献

相关主题

期刊订阅